Walleye Capital’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Walleye Capital’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,924	Closed	-$25K	–	2789
2021 Q4	$25K	Buy	+10,924	New	+$37K	﹤0.01%	1892
2021 Q3	–	Sell	-23,877	Closed	-$106	–	1947
2021 Q2	$106	Buy	+23,877	New	+$121K	﹤0.01%	1165

Other funds holding LOGC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCA

Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Walleye Capital's LOGC Position: Q1 2022 in Review

Walleye Capital sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2022, closing a stake of 10,924 shares — an estimated $25K sold.

Walleye Capital first reported a position in LOGC in Q2 2021 and held it in 2 quarters. The position peaked at $25K in Q4 2021. 46 funds tracked by Wall St. Rank hold LOGC as of Q1 2022.

Walleye Capital reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Walleye Capital sold 10,924 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $25K.
Walleye Capital first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
Walleye Capital's LogicBio Therapeutics, Inc. Common Stock position peaked at $25K in Q4 2021.
46 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Walleye Capital's 13F filing for Q1 2022, filed 16 May 2022.